Blocking hemophilic arthropathy.
暂无分享，去创建一个
[1] C. Esmon,et al. Selective inhibition of activated protein C anticoagulant activity protects against hemophilic arthropathy. , 2022, Blood.
[2] F. Peyvandi,et al. Hemophilic arthropathy: Current knowledge and future perspectives , 2021, Journal of thrombosis and haemostasis : JTH.
[3] P. Ellinger,et al. Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia , 2020, Nature Communications.
[4] C. Esmon,et al. EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice. , 2020, Blood.
[5] A. Shapiro,et al. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents , 2018, Journal of thrombosis and haemostasis : JTH.
[6] M. Manetti,et al. Pathophysiology of Hemophilic Arthropathy , 2017, Journal of clinical medicine.
[7] A. Harris,et al. Hemophilic Arthropathy. , 2017, Orthopedics.
[8] Tsukasa Suzuki,et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model , 2012, Nature Medicine.
[9] C. Esmon,et al. Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride‐induced septic shock , 2009, Journal of thrombosis and haemostasis : JTH.
[10] F. Loth. [Hemophilic arthropathy]. , 1962, Chirurgia narzadow ruchu i ortopedia polska.